Elevation Oncology provides updates on differentiated ADC programs and upcoming milestones

CAR-T Digest - August 2020

13 Jan 2025: Elevation Oncology provides updates on differentiated ADC programs and upcoming milestones

Elevation Oncology initiated dosing in a Phase 1 clinical trial evaluating EO-3021, a Claudin 18.2 ADC, in combination with ramucirumab or dostarlimab for advanced gastric/GEJ cancer
Initial data from the combination cohort of the trial is expected to be reported in Q’4 2025 or Q’1 2026
The company is on track to report additional monotherapy data from dose escalation and expansion cohorts of the ongoing Phase 1 clinical trial in the first half of 2025
Elevation Oncology plans to present preclinical data for its HER3 ADC, EO-1022, in the first half of 2025 and file an Investigational New Drug (IND) application in 2026
The company aims to leverage EO-3021’s differentiated safety profile and anti-tumor activity to improve outcomes in advanced gastric/GEJ cancer in earlier treatment lines
Elevation Oncology is focusing on exploring combination therapies for EO-3021 in the first- and second-line settings, with promising initial data supporting its potential